The New York Times Acknowledges Mistakes on Marijuana Deregulation
In a recent editorial, the New York Times editorial board confessed to previous errors regarding marijuana deregulation. They reflected on how some earlier beliefs about legalization now seem outdated.
The editorial points out that their previous stance—that marijuana is typically non-addictive—has not held up under scrutiny. For instance, back in 2014, they compared marijuana regulation to the Prohibition era, suggesting that the legalization process would not lead to significant increases in usage.
The earlier piece, written by Phillip M. Boffey, emphasized that marijuana was not addictive like heroin, but it could still create a psychological dependence that was tough to overcome. He cited findings from a study, noting that heavy users might build a tolerance and face withdrawal symptoms when stopping.
However, the editorial board has now recognized that many of those predictions have proved incorrect; they noted that legalization has resulted in increased marijuana use.
Recent research indicates daily marijuana use is much higher now, almost tripling that of alcohol usage. This uptick in consumption has consequently led to higher addiction rates, contrary to earlier beliefs that marijuana was relatively harmless. Some studies have shown links between regular use and increased risks for mental health issues, including schizophrenia.
Additionally, a previous 2014 editorial had warned about the connection between frequent marijuana use and poor academic outcomes, as well as the issues surrounding minors having easy access to the drug.
Ultimately, the editorial expressed that the decision to legalize marijuana without adequate regulations has resulted in repercussions that many did not foresee.
Currently, 24 states and the District of Columbia have legalized recreational marijuana, while another 16 states allow its medical use only. In December 2025, President Donald Trump signed an executive order aimed at reclassifying marijuana to improve research access and cannabinoid product availability.
